In patients with multiple myeloma (MM), the use of donor lymphocyte infusion (DLI) after allo-SCT is well established to induce a graft-versus-myeloma reactivity. Response rates of 30-50% in relapsed MM patients have been reported. 1, 2 Several studies have shown that the novel agents in the treatment of MM bortezomib, thalidomide and lenalidomide, besides their anti-myeloma effect, also have immune-modulating effects that may enhance the graft-versus-myeloma reaction. 3, 4 In this retrospective analysis, we evaluated the anti-myeloma effect of bortezomib in combination with DLI in 30 patients with MM relapsed after allo-SCT from two Dutch transplant centres (Nijmegen n ¼ 15 and Utrecht n ¼ 15). At relapse or in case of disease persistence, bortezomib was given to induce a myeloma response. In patients with more than a partial response this was followed by DLI to boost graft-versus-myeloma reactivity and to further improve the remission status, as DLI is considered a standard treatment policy in relapsed or persistent myeloma after allo-SCT. 5 The patient population included 23 male and 7 female patients with a median age of 59 years (range 38-75 years). All patients were treated according to standard first-line protocols, followed by allo-SCT. Before 2006, the conditioning regimen was according to the HOVON-54 study with 2 Gy TBI and an unmanipulated graft (n ¼ 12). For 6 patients, all of whom were transplanted before 2003, a myeloablative regimen was used, and for the other 12 patients a reduced intensity conditioning (RIC) regimen was used. Seven of these 18 patients received a T-cell-depleted graft, while 11 patients received an unmanipulated graft. All 30 patients received bortezomib for relapse after allo-SCT followed by DLI.
Bortezomib was given i.v. at 1.3 mg/m 2 , on days 1, 4, 8 and 11 of a 21-day cycle. DLI was planned after two or three cycles of bortezomib. No dexamethasone was added, as dexamethasone may influence the immunological effect of the DLI. DLI was not given if patients showed no response on bortezomib treatment, with the exception of patients who had responded to DLI before. Patients were scheduled to receive up to 6 cycles of bortezomib. The number of cycles actually given depended on the patient's condition, toxicity, GVHD and the actual response. If DLI was given before, the DLI dose was started from the highest dose already given. Patients with GVHD, either after alloSCT or after previous DLI, received a low dose of 0.05 Â 10 8 T cells/kg. Patients who were not treated with DLI before received 0.1 Â 10 8 T cells/kg. DLI was given at escalating doses if no complete response was observed.
CR was defined as complete disappearance of M-protein from the blood and/or urine by immunofixation and normalization of BM plasma cells. PR was defined as a decrease of more than 50% of the serum M-protein and a decrease in urinary light-chain excretion of more than 90% or to less than 0.2 g/24 h. Serum-free light chain assay was used to evaluate patients with oligo-secretory disease, according to the response criteria for MM described by Durie et al. 6 The clinical characteristics and outcomes of patients until the date of analysis (1 November 2008) are summarized in Table 1 . The median age at the start of bortezomib was 57 years (range 35-70 years); the median number of bortezomib cycles was 4.4. Nine patients received bortezomib without DLI because these patients did not achieve an objective response (n ¼ 7) or developed severe toxicity on bortezomib (n ¼ 2). The other 21 patients received bortezomib followed by DLI; out of these, 13 patients continued with bortezomib after DLI. Eight of the 30 patients reached CR (27%) and 10 patients achieved a very good PR or PR (33%). Of these 18 (60%) responding patients, 14 were treated with bortezomib followed by DLI and 10 continued bortezomib treatment after DLI. Seven patients reached stable disease after multiple bortezomib treatments, whereas five showed progressive disease (PD).
Eleven of 30 patients (eight of 21 who received DLI and 3 who did not receive DLI), developed GVHD; 5 acute, 3 chronic and 3 both acute and chronic GVHD. According to the GVHD staging described by Glucksberg et al., 7 of the eight patients with acute GVHD, four patients developed a grade 1, two a grade 2, one a grade 3 and one a grade 4 GVHD.
In one of the patients with a grade 2 acute GVHD, bortezomib treatment was discontinued because of the severity of GVHD and immune suppressive therapy was started. Chronic GVHD was based on the Seattle criteria, 8 with all six patients developing extensive chronic GVHD. One of these died because of severe sepsis.
Among the 18 responding patients, 7 experienced GVHD after treatment with bortezomib and DLI, and 1 patient developed GVHD while on bortezomib without DLI. Of the 12 non-responders, 4 patients developed GVHD, of whom 2 did not receive DLI. In these patients the severity of GVHD did not relate to the number of DLIs. Therefore, development of GVHD was as frequent in responding as in non-responding patients.
Disease-free survival (DFS) was defined as the time from start of treatment with bortezomib to progression or death from any cause, whichever occurred first. Overall survival was estimated until the date of analysis (1 November 2008). Kaplan-Meier curves are shown in Figure 1 . The median survival time of all 30 patients was 12.7 months (range 0.9-35 months). The median DFS of the responding patients was 23.2 months, compared with 6.6 months of the non-responding patients. No significant difference was seen in median DFS between patients developing GVHD and patients not developing GVHD (11.5 vs 13.9 months). The median DFS of patients receiving DLI was 15.6 months and of patients not receiving DLI was 5.6 months. The 8 CR patients had a median DFS of 22.2 months. Of these patients, five showed a continuous CR (CCR) until the date of analysis. Two patients out of the five reaching CCR experienced GVHD and all five received DLIs after treatment with bortezomib. At the last follow-up (November 2009) four out of the five CCR patients had experienced a relapse. The fifth patient died in CCR from GVHD.
Several studies have shown that the novel agents' (bortezomib, thalidomide and thalidomide derivatives) may have immune-modulating effects, resulting in enhancement of graft-versus-tumor (GVT) reactions without stimulation of GVHD. [3] [4] [5] The dissociation of GVHD and GVT is of vital importance in improving the efficacy of alloSCT and DLI. In this analysis we retrospectively collected data on the efficacy of bortezomib re-induction therapy in patients with relapsed or persistent MM after allo-SCT and the effect of the combination with DLI. DLI, being the standard treatment at relapse for allo-SCT patients, was combined with bortezomib, based on studies that showed synergistic effects. In these studies, the authors hypothesize that bortezomib treatment after DLI resulted in enhancement of GVT reactivity without enhancing GVHD and therefore improving the response rates. Sun et al.
3 assessed GVT responses in advanced Letter to the Editor leukemia-bearing mice and showed that the combination of allogeneic SCT and T-cells with bortezomib significantly increased the survival. They concluded that bortezomib might be of value in preventing GVHD and in preserving or promoting GVT responses. In a study by Kro¨ger et al., 4 low-dose thalidomide was followed by DLI in 18 patients with progressive or residual disease and prior ineffective DLI after allo-SCT to improve the anti-myeloma effect of DLI. Only a few patients experienced GVHD and the 2-year estimated progression-free survival was 84%, with an overall response rate of 67 and 22% CR, which is a higher response rate than that reported from use of thalidomide as a single drug.
Van de Donk et al. 5 evaluated DLIs for relapsed (n ¼ 48) or persistent (n ¼ 15) MM following non-myeloablative allo-SCT. A response in 38% of the patients with a 19% CR was seen. Interestingly, all patients treated with bortezomib responded, including two patients with a CCR.
In our series, about a third (9/30) of the patients did not receive DLIs. Remarkably, three patients developed GVHD without receiving DLI, contradictory to the described immune-suppressive effect of bortezomib. After the last date of analysis, only one patient did not experience a relapse but died in ongoing remission of GVHD.
We conclude from our data that although there might be a synergistic effect of bortezomib and DLI, this combined approach did not result in durable remissions, which should be the perspective in an allotransplant setting accepting a significant GVHD and reduced quality of life.
